CA2939655A1 - Modulateurs de caspase 6 - Google Patents

Modulateurs de caspase 6 Download PDF

Info

Publication number
CA2939655A1
CA2939655A1 CA2939655A CA2939655A CA2939655A1 CA 2939655 A1 CA2939655 A1 CA 2939655A1 CA 2939655 A CA2939655 A CA 2939655A CA 2939655 A CA2939655 A CA 2939655A CA 2939655 A1 CA2939655 A1 CA 2939655A1
Authority
CA
Canada
Prior art keywords
treatment
caspase
neurological disease
pharmaceutical composition
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2939655A
Other languages
English (en)
Inventor
Medhi Mike Khankischpur
Olga PETINA
Detlef Geffken
Dagmar ERNHOEFER
Michael Hayden
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Universitaet Hamburg
Original Assignee
University of British Columbia
Universitaet Hamburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of British Columbia, Universitaet Hamburg filed Critical University of British Columbia
Publication of CA2939655A1 publication Critical patent/CA2939655A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/02Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups
    • C07C251/28Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having nitrogen atoms of imino groups acylated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2939655A 2014-02-14 2015-02-14 Modulateurs de caspase 6 Abandoned CA2939655A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US61/939,922 2014-02-14
US201462033401P 2014-08-05 2014-08-05
US62/033,401 2014-08-05
PCT/IB2015/000144 WO2016020732A1 (fr) 2014-08-05 2015-02-14 Modulateurs de caspase 6

Publications (1)

Publication Number Publication Date
CA2939655A1 true CA2939655A1 (fr) 2016-02-11

Family

ID=55263221

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2939655A Abandoned CA2939655A1 (fr) 2014-02-14 2015-02-14 Modulateurs de caspase 6

Country Status (6)

Country Link
EP (1) EP3129027A4 (fr)
JP (1) JP2018522812A (fr)
AU (1) AU2015298491A1 (fr)
CA (1) CA2939655A1 (fr)
DE (1) DE112015001269T5 (fr)
WO (1) WO2016020732A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3265445B1 (fr) 2015-03-06 2021-05-05 Pharmakea, Inc. Inhibiteurs de la lysyl oxydase-like 2 et utilisations desdits inhibiteurs
AU2016229268B2 (en) 2015-03-06 2020-09-10 Pharmakea, Inc. Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof
CA3013917A1 (fr) 2016-02-09 2017-08-17 Pharmakea, Inc. Inhibiteurs quinolinone de la lysyl oxydase-like 2 et utilisations desdits inhibiteurs
CA3036064A1 (fr) 2016-09-07 2018-03-15 Pharmakea, Inc. Formes cristallines d'un inhibiteur de lysyl oxydase de type 2 et leurs procedes de fabrication
WO2018048942A1 (fr) 2016-09-07 2018-03-15 Pharmakea, Inc. Utilisations d'un inhibiteur d'homologue 2 de lysyl-oxydase
BR112022009881A2 (pt) * 2019-11-22 2022-10-11 Univ California Inibidores de caspase 6 e usos dos mesmos

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0818439B1 (fr) * 1996-07-02 1999-10-13 Nisshin Flour Milling Co., Ltd. Dérivés d'imides
EP2102189B1 (fr) * 2006-12-15 2015-07-29 Bristol-Myers Squibb Company Analogues d'arylpropionamide, d'arylacrylamide, d'arylpropynamide ou d'arylméthylurée en tant qu'inhibiteurs du facteur xia
WO2010017408A1 (fr) * 2008-08-06 2010-02-11 The Buck Institute For Age Research Inhibiteurs de caspase, et leurs utilisations

Also Published As

Publication number Publication date
WO2016020732A1 (fr) 2016-02-11
DE112015001269T5 (de) 2017-06-08
AU2015298491A1 (en) 2016-09-01
JP2018522812A (ja) 2018-08-16
EP3129027A1 (fr) 2017-02-15
EP3129027A4 (fr) 2017-06-21

Similar Documents

Publication Publication Date Title
CA2939655A1 (fr) Modulateurs de caspase 6
AU2017201599B2 (en) APP SPECIFIC BACE INHIBITORS (ASBIs) AND USES THEREOF
EP2420235A1 (fr) Procédés et polythérapies pour traiter la maladie d'Alzheimer
CN102046151A (zh) 靶向内质网的脂质体
JP6595345B2 (ja) コンフォメーション病におけるβタンパク質凝集の新規の分子モジュレーターとしての化学シャペロニン
JP2023057082A (ja) ゲムカベン、薬学的に許容されるその塩、その組成物、およびその使用方法
CN116867488A (zh) 用于治疗干性老年性黄斑变性(amd)的组合物
US9974767B2 (en) Statins in the treatment of muscular dystrophies and myopathies
CA3154596A1 (fr) Compositions solides comprenant un inhibiteur de pcsk9 et un sel d'acide n-(8-(2-hydroxybenzoyl)amino) caprylique
JP2019503356A (ja) エンドソーマルgタンパク質共役受容体のトリパータイト・モジュレーター
EP2403859A2 (fr) Pince moléculaire pour le traitement d'amyloses
US20190192524A1 (en) Modulators of Caspase-6
JP6314135B2 (ja) in−vivoで神経変性疾患(特にアルツハイマー病)に活性なリポソーム
RU2410376C2 (ru) Противовоспалительные агенты
CA3144618A1 (fr) Compositions solides comprenant un derive d'egf(a) et un sel d'acide n-(8-(2-hydroxybenzoyl) amino)caprylique
EP1931394A2 (fr) Inhibiteurs de l'interaction du domaine apoe4 et methodes d'utilisation
Imbimbo et al. Semagacestat, a gamma-secretase inhibitor for the potential treatment of Alzheimer’s disease
KR20210093900A (ko) 젬카빈, 이의 약학적으로 허용가능한 염, 이의 조성물 및 이의 사용 방법
IL295452A (en) Use of cyclosporine analogues for treating fibrosis
HUE034353T2 (en) Preparation containing a benzothiazolone compound
WO2017222042A1 (fr) Composition pharmaceutique ophtalmique
PT1551412E (pt) COMPOSIÇÕES FARMACjUTICAS PARA O TRATAMENTO DE DOENÇAS ASSOCIADAS ÀS NEUROTROFINAS
Gado et al. Physicochemical properties for potential Alzheimer’s disease drugs
KR20230159546A (ko) 신경학적 질환을 치료하기 위한 조성물 및 방법
US20080227806A1 (en) Novel Drugs for Dementia

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20200214